Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios

Size: px
Start display at page:

Download "Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios"

Transcription

1 Applying CPT and HCPCS C-Codes and Rules for Drug Administration Services to Clinical Scenarios

2 IMPORTANT PLEASE READ The information provided in this handout is informational only and should not be taken as an official answer of how to report codes and units for the services described in these clinical scenarios. Our audioconference speakers have provided this in an attempt to help hospitals sort through a number of drug administration reporting issues, but each hospital must make its own determination of how to report these services to Medicare and non-medicare payers. If you are confused or disagree, we urge you to request guidance from your FI and CMS. We cannot provide any further information or explanations at this time. If you have further questions, please contact Nimitt Consulting at jugna@nimitt.com to engage consulting services.

3 Answer for Clinical Example 1: Emergency Department Visit for a Gastric Ulcer Patient ED Visit Example 2006 CPT Codes for non- Medicare use 2006 HCPCS C- codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes IVP 14:00 Protonix x 1 C8952 x 1 IVP 14:10 Demoral x 1 C8952 x 1 IVP 14:15 Ativan x 1 C8952 x 1 ED Visit ED Level III x x 1 Page 1

4 Answer for Clinical Example 2: Emergency Department and Observation Visit for a Gastric Ulcer Patient ED and Observation Example 2006 CPT Codes for non- Medicare use 2006 HCPCS C- codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes IVP 14:00 Protonix x 1 C8952 x 1 IVP 14:10 Demoral x 1 C8952 x 1 IVP 14:15 Ativan x 1 C8952 x 1 ED Visit ED Level III x x 1 Observation 14:30-16:30 Admit to Obs x 2 G0378 x 2 Infusion started in Observation 14:30-16:30 Therapeutic Infusion x x 1 C8950 x 1 C8951 x 1 IVP 16:30 Dilaudid x 1 C8952 x 1 Page 2

5 Answer for Clinical Example 3: Multiple Push Injections of the Same Drug Chemo Regimen 2005 Hospital Reporting 2005 CPT 2006 C- Service Time Explanation Codes 2006 CPT Codes Codes IVP Lasix x x 1 C8952 x 1* IVP Lasix x 1 IVP Lasix x 1 IVP Lasix x CPT Codes for non- Medicare use 2006 HCPCS C-Codes for Medicare Use

6 Answer for Clinical Example 4: Concept of Concurrent Drug and CMS Administration as Presented at the CPT Symposium in Chicago 2006 CPT Codes Service Time Explanation for non- Medicare use 2006 C-Codes for Medicare Use IVPB Antibiotic x 1 C8950 x1 IVPB Antibiotic x 1 No Medicare C-code available to report concurrent infusion IVP Phenrgan x 1 C8952 x 1 This is the answer presented by physicians at the CPT meeting in Chicago. We believe that there is no way to report the second antibiotic infusion on the Medicare side given that there is no code available and also because both infusions are of the same type. If the concurrent infusion was of a different type (i.e., a chemotherapy drug infusion), then we believe guidance from Transmittal 785 would allow us to report Page 4 both the antibiotic and the chemo infusion.

7 Answer for Clinical Example 5: Two Chemotherapy Push Drugs with a Non-Chemotherapy Drug Two Different Chemo Drugs Given IVP and Non- Chemo by IVP 2006 CPT Codes Non-Medicare Use 2006 CPT and HCPCS C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 codes IVP 9:00 PS-341 (chemo) x 1 C8953 x 1 IVP 10:02 5FU (chemo) x 1 C8953 x 1 IVP 9:30 Leucovorin (nonchemo) x 1 C8952 x 1 Page 5

8 Answer to Clinical Example 6: Chemotherapy Infusion with Anti-Emetics Chemo Regimen 2006 CPT Codes for Non-Medicare use 2006 HCPCS C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes Decadron/Aloxi (nonchemo) C8952 x x 1 IVP 10:00-10:10 1 IVP 10:10-10:20 Reglan (non-chemo) x 1 C8952 x 1 IV infusion 12:20-14:20 Cisplatin (chemo) x x 1 C8954 x 1 C8955 x 1 Page 6

9 Answer to Clinical Example 7: Chemotherapy Infusion with Anti-Emetics, Pre-and- Post Hydration, and Additional Meds Chemo Regimen 2006 CPT Codes for non- Medicare use 2006 C-codes for Medicare Use Service Time Explanation 2006 Codes 2006 Codes Decadron/Aloxi (nonchemo) C8952 x x 1 IVP 10:00-10:10 1 IVP 10:10-10:20 Reglan (non-chemo) x 1 C8952 x 1 IV infusion 10:20-12:20 Hydration x 2 C8950 x 1 C8951 x 1 IV infusion 12:20-14:20 Cisplatin (chemo) x x 1 C8954 x 1 C8955 x 1 IVP 14:20-14:55 Mannitol (non-chemo) x 1 C8952 x 1 IV infusion 14:55-16:55 Hydration x 2 C8951 x 2 IV infusion 16:55-17:55 Etoposide (chemo) x 1 C8955 x 1 IVP 17:55-18:05 Bleomyocin (chemo) x 1 C8953 x 1 Page 7

10 Answer to Clinical Example 8: Concept of Sequential Drug Administration as Presented at the CPT Symposium in Chicago Chemo Regimen 2006 CPT Codes for non- Medicare use 2006 HCPCS C- Codes for Medicare Use 2006 CPT Service Time Explanation Codes 2006 C-Codes IVP 9:00-9:20 Ativan (non-chemo) x 1 C8952 x 1 IVPB 9:25-9:45 Decadron, Zofran, Benadryl (non-chemo) x 1 C8950 x 1 IV Infusion 9:45-10:45 Paraplatin (chemo) x 1 C8954 x 1 IV Infusion 10:45-11:15 Cytoxan (chemo) x 1 N/A Note: There is no sequential chemotherapy infusion C-code available to report to Medicare. Also, the total time of the Paraplatin and Cytoxan does not meet the time requirement to bill any additional hours using the C8955 add-on code. Page 8

11 Answer for Clinical Example 9: Chemotherapy Infusion and Hydration with Overlapping Time Chemo Regimen w/ hydration hour overlapping with Chemo Infusion 2006 CPT Codes for non-medicare use 2006 HCPCS C-codes for Medicare Use Service Time Explanation 2006 CPT Codes 2006 codes IVP 13:15 (15 min) Zofran (non-chemo) x 1 C8952 x 1 IV infusion 13:15-16:45 Hydration x 3 OR see below C8950 x 1 C8951 x 2 or see below Codes/units if overlapping time for Cytoxan and Taxotere is deducted (hydration then = 45 minutes) x 1 C8950 X 1 IVP 13:25-13:55 Adriamycin (chemo) x 1 C8953 x 1 IV infusion 14:00-15:30 Cytoxan (chemo) x 1 C8954 x 1 IV infusion 15:30-16:30 Taxotere (chemo) x 1 C8955 x 1 Since the hydration runs throughout the course of the chemotherapy infusion, many hospitals are only reporting the non-overlapping hydration time and not the overlapping time (i.e., not the full duration of the hydration if it overlaps). Please request clarification from your FI and/or CMS. Page 9

12 Answer to Clinical Example # 10: Concept of Concurrent Infusions Under CPT Codes vs. Medicare C-Codes 2006 CPT Codes 2006 HCPCS C- for non-medicare codes for use Medicare Use Service Time Explanation 2006 CPT Codes 2006 Codes SAMPLE FOLFOX REGIMEN Chemotherapy drug infusion 10:00 to 12:00 The drug Oxaliplatin is infused concurrently with the non-chemo Leucovorin drug through "Y" tubing. Oxaliplatin is compatible with Leucovorin, but not the second chemo drug Fluorouracil. Order reads: Oxaliplatin 85mg/m2 IVPB Run in 2 hrs x x 1 C8954 x 1 C8955 x 1 Nonchemotherapy drug infusion 10:00 to 12:00 The non-chemo drug Leucovorin is infused concurrently with the chemo drug Oxaliplatin through "Y" tubing. Order reads: Leucovorin 200mg/m2 IVPB run in 2 hrs.mg/m2 IVPB Run in 2 hrs x 1 C8950 x 1 C8951 x 1 Chemotherapy drug injection 12:10 Fluorouracil given by the hospital as an IVP x 1 C8953 x 1 There is no concurrent infusion C-code for Medicare. However, in this example, two different types of services are running concurrently (chemo and non-chemo). We believe Transmittal 785 allows for both of these services to be reported. The concept of concurrent is not well-defined, therefore hospitals should request clarification from their FI and/or CMS to determine how they will report this. We have requested official guidance but have not received a response as of Feb 3, Page 10

Infusion Coding Infusions, Pushes, Injections

Infusion Coding Infusions, Pushes, Injections Infusion Coding Infusions, Pushes, Injections Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions

More information

Outpatient Infusion Coding & Documentation: Take Your Skills to a Higher Level

Outpatient Infusion Coding & Documentation: Take Your Skills to a Higher Level Outpatient Infusion Coding & Documentation: Take Your Skills to a Higher Level Presented by Robin Zweifel, BS, MT(ASCP) Marta Kramer, MBA, CCS-P.. June 27, 2014 Disclaimer MedLearn Publishing has prepared

More information

BILLING & CODING MEDICAL ONCOLOGY. Risë Marie Cleland, Oplinc Inc. June 2017

BILLING & CODING MEDICAL ONCOLOGY. Risë Marie Cleland, Oplinc Inc. June 2017 BILLING & CODING MEDICAL ONCOLOGY Risë Marie Cleland, Oplinc Inc. June 2017 CPT is a Registered Trademark of the AMA CPT copyright 2017 American Medical Association. All rights reserved. Fee schedules,

More information

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Billing for Infusion Services in an Outpatient Neurology Clinic Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Overview of Infusion Billing Codes Current Procedure Terminology

More information

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily

Type Days HRG Procurement 1 Cost and Volume Delivery 1 Day case. Weekly for 30 weeks. 1-14inc Capecitabine 1250mg/m² twice daily Colorectal - Adjuvant Standard adjuvant therapy for Duke's C Day(s) Drug Dose Route Comments and high risk Duke's B Colorectal cancer 5-FU/FA Weekly 1 Folinic acid 50mg IV IV Bolus injection via fast running

More information

Coding Tips, Hints & Pointers for Medical Oncology Billing

Coding Tips, Hints & Pointers for Medical Oncology Billing Coding Tips, Hints & Pointers for Medical Oncology Billing Empire State Hematology & Oncology Society Meeting October 5, 2018 Disclaimer When a third party payer is involved, the determination of reimbursement

More information

Infusion Coding. Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC. Codes

Infusion Coding. Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC. Codes Infusion Coding Is this going to hurt? Presented by: Annalynn Hall, M.Ed, CPC, CHONC 1 Codes The codes used in this presentation are copyrighted by the AMA Review all codes and code descriptions for appropriate

More information

Davis s Drug Guide Scavenger Hunt 15 th Edition

Davis s Drug Guide Scavenger Hunt 15 th Edition Davis s Drug Guide Scavenger Hunt 15 th Edition This handout is designed to assist you in locating information in the Davis s Drug Guide. Take advantage of the many resources in this text!! Locate the

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119 Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Jonathan Dickinson, LCL Xeloda

Jonathan Dickinson, LCL Xeloda Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG DRUG AND TREATMENT Available at: ALL Adult Facilities Non Categorized SUB ED Abdominal Pain Protocol(SUB)* ***The above subphase is available at the end of the plan*** SUB ED Abdominal Pain Protocol Lab

More information

Ensuring Accuracy: Chargemaster and Outpatient Facility Coding

Ensuring Accuracy: Chargemaster and Outpatient Facility Coding Ensuring Accuracy: Chargemaster and Outpatient Facility Coding Catrena L. Smith CCS, CCS-P, CPC, PCS Disclaimer This material is provided as education for coders and other personnel involved in the coding

More information

Toxicities of Chemotherapy Regimens used in Early Breast Cancer

Toxicities of Chemotherapy Regimens used in Early Breast Cancer Toxicities of Chemotherapy Regimens used in Early Breast Cancer CERCIT Workshop February 17, 2012 Carlos H Barcenas, M.D., M.S. Fellow Hematology-Oncology MD Anderson Cancer Center CERCIT Scholar Outline

More information

Cancer SLO Practice (online set) Page 1 of 5

Cancer SLO Practice (online set) Page 1 of 5 Cancer SLO Practice (online set) Page 1 of 5 1. Aranesp is? A. Darbepoetin alfa B. Filgrastim C. Epoetin alfa D. Sargramostim E. Pegfilgrastim 2. BCNU is? B. Cyclophosphamide 3. Bleomycin is a natural

More information

05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage

05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage 2015 National Training Program Medicare Prescription Drug Coverage Parts A, B and D Session Objectives This session should help you Differentiate when/under what scenarios drugs are covered under the various

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,

More information

Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran

Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center

More information

Reporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer.

Reporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer. Reporting Mammograms for Medicare Patients Coding these preventive procedures depends on the payer. By Barbara Aubry, RN, CPC, CPMA, CHCQM, FABQAURP For 2017, the American Medical Association (AMA) deleted

More information

Are we making progress? Marked reduction in operative morbidity and mortality

Are we making progress? Marked reduction in operative morbidity and mortality Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional

More information

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?

Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Re: Comprehensive Ambulatory Payment Classification Methodology

Re: Comprehensive Ambulatory Payment Classification Methodology Tiffany Swygert Director, Division of Outpatient Care Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Comprehensive Ambulatory Classification Methodology

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer

The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,

More information

亞東紀念醫院 Breast Cancer 化學治療處方集

亞東紀念醫院 Breast Cancer 化學治療處方集 亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,

More information

ADULT Updated: September 4, 2018

ADULT Updated: September 4, 2018 Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles

More information

Genomic Health, Inc. Oncotype DX Colon Cancer Assay Clinical Compendium March 30, 2012

Genomic Health, Inc. Oncotype DX Colon Cancer Assay Clinical Compendium March 30, 2012 Economic Validity Eligibility and Addressability for Use of the Assay An important distinction should be made between the total population of patients eligible for the Oncotype DX Colon Cancer assay, and

More information

Medicare Part C Medical Coverage Policy

Medicare Part C Medical Coverage Policy Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications

More information

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER

CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain

More information

Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES

Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES Optimal adjuvant therapy for colon cancer is FOLFOX for 6 cycles YES Bassel F. El-Rayes 1 Background Standard of care for resected stage III colon cancer is six months of adjuvant oxaliplatin-based therapy

More information

NCCN Chemotherapy Order Templates

NCCN Chemotherapy Order Templates USER GUIDE NCCN Chemotherapy Order Templates (NCCN Templates ) Access to the NCCN Chemotherapy Order Templates (NCCN Templates ) for non-commercial users is available via subscription. Prior to accessing

More information

ONCOLOGY LETTERS 2: , 2011

ONCOLOGY LETTERS 2: , 2011 ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following

More information

OVERALL CLINICAL BENEFIT

OVERALL CLINICAL BENEFIT cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate

More information

Chemotherapy of Breast Cancer

Chemotherapy of Breast Cancer Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation

More information

C ODING PAIN C LINICS. After attending this presentation, attendee will be able to: Coding Check List

C ODING PAIN C LINICS. After attending this presentation, attendee will be able to: Coding Check List Home Town Health Take the Pain out of Coding Pain Clinics J E NAN C U S TER C P C, C C S, C D I P AH IMA A PPROVED IC D - 1 0 - C M/PC S T RAINER AND A MBASSADOR D IRECTOR OF C ODING H EALTHCARE C ODING

More information

NCCP Chemotherapy Regimen. FLOT Therapy-14 day

NCCP Chemotherapy Regimen. FLOT Therapy-14 day INDICATIONS FOR USE: FLOT Therapy-14 Regimen Code 00344a *Reimbursement Indicator INDICATION ICD10 Treatment of locally advanced ( T2) and/or nodal positive (N+) C16 resectable gastric adenocarcinoma Treatment

More information

Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma

Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness

More information

Panel Two: Evidence for Use of Maintenance Therapy

Panel Two: Evidence for Use of Maintenance Therapy Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Lisa M. Hess Diane Michael Daniel S. Mytelka Julie Beyrer Astra M. Liepa Steven Nicol

Lisa M. Hess Diane Michael Daniel S. Mytelka Julie Beyrer Astra M. Liepa Steven Nicol Gastric Cancer (2016) 19:607 615 DOI 10.1007/s10120-015-0486-z ORIGINAL ARTICLE Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective

More information

ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99)

ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) ANAPLASTIC LARGE CELL LYMPHOMA TREATMENT ROAD MAP (Modified ALCL99) CLASSIFICATION OF TREATMENT GROUPS: 1. Isolated Skin lesions, < 5 skin lesions. Treatment course: ( No treatment, wait and see approach)

More information

Oncology Competency Self Assessment

Oncology Competency Self Assessment Oncology Competency Self Assessment Directions Please circle a value for each question to provide us and the interested facilities with an assessment of your clinical experience. These values confirm your

More information

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG Available at ALL facilities Non Categorized SUB ED Chest Pain: STEMI Protocol(SUB)* SUB ED Chest Pain: STEMI Protocol Lab Orders(SUB)* ED Rainbow Tubes(SUB)* ***Reminder: Order ED Rainbow Tubes (SUB) as

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab

More information

MASCC Guidelines for Antiemetic control: An update

MASCC Guidelines for Antiemetic control: An update MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Third Line and Beyond: Management of Refractory Colorectal Cancer

Third Line and Beyond: Management of Refractory Colorectal Cancer Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting

More information

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer

Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of

More information

MP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer

MP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer MP 2.04.56 Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer Medical Policy Section Medicine Issue 12:2013 Original

More information

1-844-FAX-A360 ( )

1-844-FAX-A360 ( ) 1-844-ASK-A360 (1-844-275-2360) 1-844-FAX-A360 (1-844-329-2360) www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8 am to 8 pm ET. IMFINZI

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317 Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date: Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D. Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation

More information

Gemcitabine + Cisplatin Regimen

Gemcitabine + Cisplatin Regimen Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy 11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor

More information

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director

Symptom Management. Thomas McKain, MD, ABFM, ABHPM Medical Director Symptom Management Nausea & Vomiting Thomas McKain, MD, ABFM, ABHPM Medical Director Mr. Jones has nausea and vomiting. May I initiate Compazine from the Comfort Pak? Objectives 1. Delineate the Differential

More information

Auditors Desk Reference

Auditors Desk Reference Auditors Desk Reference 2016 Contents Chapter 1. Auditing Processes and Protocols... 1 Claims Reimbursement... 1 Role of Audits... 6 Medical Record Documentation... 9 Chapter 2. Focusing and Performing

More information

Advances in Chemotherapy of Colorectal Cancer

Advances in Chemotherapy of Colorectal Cancer Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre

More information

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry. Types I, II and III PPB

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry. Types I, II and III PPB CHILDREN S HOSPITALS AND CLINICS of MINNESOTA 2525 Chicago Avenue South Minneapolis, Minnesota 55404, USA International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Types I, II and III

More information

Reference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:

Reference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer

More information

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens

Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens 1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days

More information

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

More information

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options

Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of

More information

TESTS AND MONITORING:

TESTS AND MONITORING: BC Cancer Protocol Summary for Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy Protocol Code: GIEFFOXRT Tumour Group:

More information

Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:

Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2

More information

Injectable Opioid Shortage: February 27, 2018

Injectable Opioid Shortage: February 27, 2018 Injectable Opioid Shortage: February 27, 2018 Beginning approximately June 2017, the supply of hydromorphone injection started to become an issue across the U.S. due to demand exceeding supply per most

More information

Resectable locally advanced oesophagogastric cancer

Resectable locally advanced oesophagogastric cancer Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for

More information

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer

Disclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,

More information

Chemotherapy of colon cancers

Chemotherapy of colon cancers Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having

More information

Policy. ( Number: *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB.

Policy. (  Number: *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB. 1 of 11 (https://www.aetna.com/) Number: 0889 Policy *Pleasesee amendment forpennsylvaniamedicaidatthe endofthis CPB. Aetna considers levoleucovorin (Fusilev) medically necessary for the following indications,

More information

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal

More information

Eloxatin (Oxaliplatin)

Eloxatin (Oxaliplatin) Policy Number ELO12012011RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 09/10/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare

More information

Ping-Tsung Chen, MD; Chuang-Chi Liaw, MD

Ping-Tsung Chen, MD; Chuang-Chi Liaw, MD Original Article 167 Intravenous Ondansetron plus Intravenous Dexamethasone with Different Ondansetron Dosing Schedules during Multiple Cycles of Cisplatin-based Chemotherapy Ping-Tsung Chen, MD; Chuang-Chi

More information

Haematology, Oncology and Palliative Care Directorate.

Haematology, Oncology and Palliative Care Directorate. Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile

More information

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG DRUG AND TREATMENT Available at: ALL Adult Facilities Non Categorized SUB Protocol(SUB)* SUB Protocol Lab Orders(SUB)* ED Rainbow Tubes(SUB)* ***Reminder: Order ED Rainbow Tubes (SUB) as a separate form***

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

Pancreatic Cancer Where are we?

Pancreatic Cancer Where are we? Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer

More information

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC) Cisplatin and Vinorelbine and radiotherapy (NSCLC) Indication First-line chemotherapy for use with concomitant radical radiotherapy for early or locally advanced non-small cell carcinoma (NSCLC) ICD-10

More information

Symptom Management of Gastrointestinal Alterations

Symptom Management of Gastrointestinal Alterations Symptom Management of Gastrointestinal Alterations Parisa Tsutsumi RN, BSN, OCN, BMTCN University of Washington Medical Center Nausea and Vomiting Mucositis Taste Alterations Gastrointestinal Alterations

More information

MEDICARE RECOVERY AUDIT CONTRACTORS

MEDICARE RECOVERY AUDIT CONTRACTORS MEDICARE RECOVERY AUDIT CONTRACTORS RAC ROUND-UP SUBSCRIPTION SERVICE RACS: What Are We Learning? Newly Approved Issues: Part 2 September 1, 2009 2009 Aegis Compliance & Ethics Center, LLP 1 1 Faculty

More information

Fluorouracil, Oxaliplatin and Docetaxel (FLOT)

Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Indication Perioperative chemotherapy for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. ICD-10 codes Codes with a prefix C15,C16 Regimen

More information

Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs

Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services US Department of Health and Human Services Attention: CMS-1695-FC P.O. Box 8013, 7500 Security Boulevard Baltimore, MD 21244-1850

More information

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Front-line treatment in young. Role of maintenance therapy. Rome 2017 Prof Le Gouill S.

Front-line treatment in young. Role of maintenance therapy. Rome 2017 Prof Le Gouill S. Front-line treatment in young patients with MCL: Role of maintenance therapy Rome 2017 Prof Le Gouill S. Is there a need for maintenance for young MCL patients? Is there a need for maintenance for young

More information

Nausea and Vomiting. Symptom Management of Gastrointestinal Alterations. Gastrointestinal Alterations. Nausea/Vomiting Patterns

Nausea and Vomiting. Symptom Management of Gastrointestinal Alterations. Gastrointestinal Alterations. Nausea/Vomiting Patterns Symptom Management of Gastrointestinal Alterations Elise Frans, MN, RN, CWON Oncology Clinical Nurse Specialist University of Washington Medical Center delterzo@uw.edu Nausea and Vomiting Mucositis Taste

More information

CBC with Differential. PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

CBC with Differential. PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG DRUG AND TREATMENT Non Categorized SUB ED Snakebite Protocol (SUB)* Non Categorized ***(NOTE)*** This plan is designed to be used as part of a larger plan, not independently. Please do NOT order individually.

More information

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

More information

Cyramza (ramucirumab)

Cyramza (ramucirumab) Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications

More information